Management of Anticoagulation in Patients Requiring Surgery

Preoperative Discontinuation of Rivaroxaban

For patients with renal impairment (CrCl 30-50 mL/min), longer discontinuation periods of rivaroxaban should be considered due to delayed drug clearance, as stated by the Anaesthesia journal 1
Complete blood count should be ordered to assess baseline hemoglobin and platelet count before surgical intervention, according to Praxis Medical Insights 2

Patients with small bowel obstruction requiring urgent surgery (signs of peritonitis, strangulation, or bowel ischemia) need immediate intervention regardless of anticoagulation status, as recommended by the World Journal of Emergency Surgery 3
Non-operative management should be tried in patients with adhesive small bowel obstruction without signs of peritonitis, strangulation, or bowel ischemia, as suggested by the World Journal of Emergency Surgery 3

No bridging anticoagulation is needed when discontinuing rivaroxaban, as stated in the Anaesthesia journal 1
For patients with creatinine clearance between 30-50 mL/min, consider extending the discontinuation period of rivaroxaban to 48 hours, according to the Anaesthesia journal 1

For patients with low bleeding risk and adequate hemostasis, rivaroxaban can be resumed at least 6 hours after the end of the procedure, as recommended by Praxis Medical Insights 2
If bleeding risk remains high or hemostasis is incomplete, consider delaying full anticoagulation and using prophylactic doses of anticoagulants, as suggested by the Anaesthesia journal 1

Unnecessary bridging with heparin products can increase bleeding risk without reducing thrombotic risk, as stated in the Anaesthesia journal 1
Resuming full-dose anticoagulation too early in cases with incomplete hemostasis can lead to significant bleeding complications, according to Praxis Medical Insights 2